Cellular uptake and antitumour activity of paclitaxel incorporated into trilaurin-based solid lipid nanoparticles in ovarian cancer. (17th April 2013)

• Record Type: Journal Article
• Authors: Xu, Wenting; Lim, Soo-Jeong; Lee, Mi-Kyung
• Is Part Of: Journal of microencapsulation. Volume 30:Number 8(2013:Dec.)
• Page Start: 755
• Page End: 761
• Publication Date: 2013-04-17
• Subjects: Ovarian cancer -- paclitaxel -- SKOV-3 -- solid lipid nanoparticles -- trilaurin; Microencapsulation -- Periodicals; Controlled release technology -- Periodicals; 615.19
• DOI: 10.3109/02652048.2013.788083
• Languages: English
• ISSNs: 0265-2048

Abstract

Abstract: Trilaurin-based solid lipid nanoparticles (TL-SLNs) containing paclitaxel (PTX) were prepared by hot-melt high-pressure homogenisation and subsequent freezing and thawing. PTX-containing TL-SLNs showed 160.0 ± 15.8 nm of mean particle size and −43.9 mV of zeta potential. Scanning electron microscopy also revealed the spherical shape and submicron-size of the TL-SLNs. Differential scanning calorimetry measurement presented melting transition peak of TL in SLNs indicating the solidified state of the core lipid. The prepared TL-SLNs were physically stable without significant particle size changes at 4 °C for 2 months. The amounts of uptake into the human ovarian cancer cells, SKOV-3, were similar between PTX delivered in Cremophor EL-based formulation and TL-SLNs. In vitro and in vivo antitumour activity of PTX in TL-SLNs was comparable to the commercial Cremophor EL-based formulation in SKOV-3. These results suggest that PTX-loaded TL-SLNs have promising potential as an alternative parenteral formulation for PTX.